DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies

Vaccine

Volumn 27, Issue 42, 2009, Pages 5772-5780

  Bellier, Bertrand ^a,b,c   Huret, Christophe ^a,b,c   Miyalou, Mathilde ^a,b,c   Desjardins, Delphine ^a,b,c,d   Frenkiel, Marie Pascale ^e   Despres, Philippe ^e   Tangy, Fréderic ^b   Dalba, Charlotte ^f   Klatzmann, David ^a,b,c,d  

^a SORBONNE UNIVERSITÉ   (France)

^b CNRS   (France)

^c Unit of Dermatology   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e INSTITUT PASTEUR   (France)

^f EPIXIS SA   (France)

Author keywords

DNA vaccine; Neutralizing antibody; Virus like particle

Indexed keywords

ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; DNA VACCINE; GAG PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 4; INTERLEUKIN 6; LENTIVIRUS VECTOR; NEUTRALIZING ANTIBODY; PLASMID DNA; PLASMID VECTOR; POL PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; MOUSE; MURINE LEUKEMIA VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; RETROVIRUS; VESICULAR STOMATITIS VIRUS; VIRUS LIKE AGENT; WEST NILE FLAVIVIRUS;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; FEMALE; GENE PRODUCTS, ENV; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; NEUTRALIZATION TESTS; RETROVIRIDAE; VACCINES, DNA; VESICULOVIRUS; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES; WEST NILE VIRUS;

EID: 69949130823     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.07.059     Document Type: Article

References (59)

1. Tang D.C., DeVit M., and Johnston S.A. Genetic immunization is a simple method for eliciting an immune response. Nature 356 6365 (1992) 152-154
2. Fuller D.H., Loudon P., and Schmaljohn C. Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods 40 1 (2006) 86-97
3. Kutzler M.A., and Weiner D.B. DNA vaccines: ready for prime time?. Nat Rev Genet 9 10 (2008) 776-788
4. Liu M.A., and Ulmer J.B. Human clinical trials of plasmid DNA vaccines. Adv Genet 55 (2005) 25-40
5. Jechlinger W. Optimization and delivery of plasmid DNA for vaccination. Expert Rev Vaccines 5 6 (2006) 803-825
6. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., and Staprans S.I. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292 5514 (2001) 69-74
7. Dale C.J., Thomson S., De Rose R., Ranasinghe C., Medveczky C.J., Pamungkas J., et al. Prime-boost strategies in DNA vaccines. Methods Mol Med 127 (2006) 171-197
8. Appay V., Douek D.C., and Price D.A. CD8+ T cell efficacy in vaccination and disease. Nat Med 14 6 (2008) 623-628
9. Milich D.R., and McLachlan A. The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science 234 4782 (1986) 1398-1401
10. Ulrich R., Nassal M., Meisel H., and Kruger D.H. Core particles of hepatitis B virus as carrier for foreign epitopes. Adv Virus Res 50 (1998) 141-182
11. Bachmann M.F., Hengartner H., and Zinkernagel R.M. T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction?. Eur J Immunol 25 12 (1995) 3445-3451
12. Kim M., Qiao Z.S., Montefiori D.C., Haynes B.F., Reinherz E.L., and Liao H.X. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies. AIDS Res Hum Retroviruses 21 1 (2005) 58-67
13. Karlsson Hedestam G.B., Fouchier R.A., Phogat S., Burton D.R., Sodroski J., and Wyatt R.T. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6 2 (2008) 143-155
14. Zhou T., Xu L., Dey B., Hessell A.J., Van Ryk D., Xiang S.H., et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445 7129 (2007) 732-737
15. McBurney S.P., Young K.R., and Ross T.M. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. Virology 358 2 (2007) 334-346
16. Hammonds J., Chen X., Fouts T., DeVico A., Montefiori D., and Spearman P. Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization. J Virol 79 23 (2005) 14804-14814
17. Kovacsovics-Bankowski M., Clark K., Benacerraf B., and Rock K.L. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci USA 90 11 (1993) 4942-4946
18. Bachmann M.F., Lutz M.B., Layton G.T., Harris S.J., Fehr T., Rescigno M., et al. Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes. Eur J Immunol 26 11 (1996) 2595-2600
19. Chackerian B. Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines 6 3 (2007) 381-390
20. Fagan E.A., Williams R., and Eddleston A.L. Hepatitis B vaccine: responder status and timing of additional booster doses. Lancet 2 8558 (1987) 561
21. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 9447 (2004) 1757-1765
22. Bellier B., Dalba C., Clerc B., Desjardins D., Drury R., Cosset F.L., et al. DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant. Vaccine 24 14 (2006) 2643-2655
23. Dalba C., Bellier B., Kasahara N., and Klatzmann D. Replication-competent vectors and empty virus-like particles: new retroviral vector designs for cancer gene therapy or vaccines. Mol Ther 15 3 (2007) 457-466
24. Desjardins D., Huret C., Dalba C., Kreppel F., Kochanek S., Cosset F.L., et al. Recombinant retrovirus-like particle forming DNA vaccines in prime-boost immunization and their use for HCV vaccine development. J Gene Med (2009)
25. Bachmann M.F., Rohrer U.H., Kundig T.M., Burki K., Hengartner H., and Zinkernagel R.M. The influence of antigen organization on B cell responsiveness. Science 262 5138 (1993) 1448-1451
26. Burns J.C., Friedmann T., Driever W., Burrascano M., and Yee J.K. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 90 17 (1993) 8033-8037
27. Bachmann M.F., Fehr T., Freer G., Hengartner H., and Zinkernagel R.M. Correlation of tolerogenicity of a viral antigen with its immunogenicity. J Immunol 158 11 (1997) 5106-5111
28. Roehrig J.T., Staudinger L.A., Hunt A.R., Mathews J.H., and Blair C.D. Antibody prophylaxis and therapy for flavivirus encephalitis infections. Ann N Y Acad Sci 951 (2001) 286-297
29. Dupuy F.P., Mouly E., Mesel-Lemoine M., Morel C., Abriol J., Cherai M., et al. Lentiviral transduction of human hematopoietic cells by HIV-1- and SIV-based vectors containing a bicistronic cassette driven by various internal promoters. J Gene Med 7 9 (2005) 1158-1171
30. Despres P., Combredet C., Frenkiel M.P., Lorin C., Brahic M., and Tangy F. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J Infect Dis 191 2 (2005) 207-214
31. Cooper C., Morley D.C., Weeks M.C., and Beale A.J. Administration of measles vaccine by dermojet. Lancet 1 7446 (1966) 1076-1077
32. Davis B.S., Chang G.J., Cropp B., Roehrig J.T., Martin D.A., Mitchell C.J., et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 75 9 (2001) 4040-4047
33. Hosie M.J., Dunsford T., Klein D., Willett B.J., Cannon C., Osborne R., et al. Vaccination with inactivated virus but not viral DNA reduces virus load following challenge with a heterologous and virulent isolate of feline immunodeficiency virus. J Virol 74 20 (2000) 9403-9411
34. Macklin M.D., McCabe D., McGregor M.W., Neumann V., Meyer T., Callan R., et al. Immunization of pigs with a particle-mediated DNA vaccine to influenza A virus protects against challenge with homologous virus. J Virol 72 2 (1998) 1491-1496
35. Ward G., Rieder E., and Mason P.W. Plasmid DNA encoding replicating foot-and-mouth disease virus genomes induces antiviral immune responses in swine. J Virol 71 10 (1997) 7442-7447
36. Ramsay A.J., Kent S.J., Strugnell R.A., Suhrbier A., Thomson S.A., and Ramshaw I.A. Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity. Immunol Rev 171 (1999) 27-44
37. Wang S., Parker C., Taaffe J., Solorzano A., Garcia-Sastre A., and Lu S. Heterologous HA DNA vaccine prime-inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine 26 29-30 (2008) 3626-3633
38. Sandrin V., and Cosset F.L. Intracellular versus cell surface assembly of retroviral pseudotypes is determined by the cellular localization of the viral glycoprotein, its capacity to interact with Gag, and the expression of the Nef protein. J Biol Chem 281 1 (2006) 528-542
39. Wool-Lewis R.J., and Bates P. Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J Virol 72 4 (1998) 3155-3160
40. Rothwangl K.B., Manicassamy B., Uprichard S.L., and Rong L. Dissecting the role of putative CD81 binding regions of E2 in mediating HCV entry: putative CD81 binding region 1 is not involved in CD81 binding. Virol J 5 (2008) 46
41. Dintzis H.M., Dintzis R.Z., and Vogelstein B. Molecular determinants of immunogenicity: the immunon model of immune response. Proc Natl Acad Sci USA 73 10 (1976) 3671-3675
42. Fehr T., Bachmann M.F., Bucher E., Kalinke U., Di Padova F.E., Lang A.B., et al. Role of repetitive antigen patterns for induction of antibodies against antibodies. J Exp Med 185 10 (1997) 1785-1792
43. Fehr T., Skrastina D., Pumpens P., and Zinkernagel R.M. T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. Proc Natl Acad Sci USA 95 16 (1998) 9477-9481
44. Jegerlehner A., Storni T., Lipowsky G., Schmid M., Pumpens P., and Bachmann M.F. Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur J Immunol 32 11 (2002) 3305-3314
45. Jegerlehner A., Tissot A., Lechner F., Sebbel P., Erdmann I., Kündig T., et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 20 25-26 (2002) 3104-3112
46. Bachmann M.F., and Zinkernagel R.M. Neutralizing antiviral B cell responses. Annu Rev Immunol 15 (1997) 235-270
47. Bachmann M.F., Kündig T.M., Speiser D.E., McKall-Faienza K., Kishara K., Mak T.W., et al. T-cell-independent antiviral B cell responses in CD45-deficient mice. Cell Immunol 175 1 (1997) 12-15
48. Gordon S. Pattern recognition receptors: doubling up for the innate immune response. Cell 111 7 (2002) 927-930
49. Spohn G., and Bachmann M.F. Exploiting viral properties for the rational design of modern vaccines. Expert Rev Vaccines 7 1 (2008) 43-54
50. Ellenberger D., Wyatt L., Li B., Buge S., Lanier N., Rodriguez I.V., et al. Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs. Virology 340 1 (2005) 21-32
51. Mariani R., Rutter G., Harris M.E., Hope T.J., Krausslich H.G., and Landau N.R. A block to human immunodeficiency virus type 1 assembly in murine cells. J Virol 74 8 (2000) 3859-3870
52. Arrode G., Hegde R., Jin Y., Singh D.K., Narayan O., and Chebloune Y. Nef modulates the immunogenicity of Gag encoded in a non-infectious HIV DNA vaccine. Vaccine 26 31 (2008) 3795-3804
53. Mumper R.J., and Cui Z. Genetic immunization by jet injection of targeted pDNA-coated nanoparticles. Methods 31 3 (2003) 255-262
54. Baxter J., and Mitragotri S. Jet-induced skin puncture and its impact on needle-free jet injections: experimental studies and a predictive model. J Control Release 106 3 (2005) 361-373
55. Kendall M. Engineering of needle-free physical methods to target epidermal cells for DNA vaccination. Vaccine 24 21 (2006) 4651-4656
56. Mitragotri S. Current status and future prospects of needle-free liquid jet injectors. Nat Rev Drug Discov 5 7 (2006) 543-548
57. Scheerlinck J.Y. Genetic adjuvants for DNA vaccines. Vaccine 19 17-19 (2001) 2647-2656
58. Sasaki S., Takeshita F., Xin K.Q., Ishii N., and Okuda K. Adjuvant formulations and delivery systems for DNA vaccines. Methods 31 3 (2003) 243-254
59. Xu R., Megati S., Roopchand V., Luckay A., Masood A., Garcia-Hand D., et al. Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines. Vaccine 26 37 (2008) 4819-4829